doi: 10.1503/cmaj.051687.
Do manufacturers of brand-name drugs engage in price competition? An analysis of introductory prices
Affiliations
- PMID: 16606961
- PMCID: PMC1421463
- DOI: 10.1503/cmaj.051687
Item in Clipboard
Do manufacturers of brand-name drugs engage in price competition? An analysis of introductory prices
CMAJ.
.
No abstract available
Figures
Fig. 1: Distribution of 33 new drugs by how their introductory prices related to the mean price of existing brand-name drugs in their therapeutic class.
Similar articles
-
The effect of generic competition on the price of brand-name drugs.Health Policy. 2004 Apr;68(1):47-54. doi: 10.1016/j.healthpol.2003.07.007. Health Policy. 2004. PMID: 15033552
-
Product-line extensions and pricing strategies of brand-name drugs facing patent expiration.J Manag Care Pharm. 2005 Nov-Dec;11(9):746-54. doi: 10.18553/jmcp.2005.11.9.746. J Manag Care Pharm. 2005. PMID: 16300418 Free PMC article.
-
Price regulation of pharmaceuticals in Canada.J Health Econ. 1998 Jan;17(1):21-38. doi: 10.1016/s0167-6296(97)00016-7. J Health Econ. 1998. PMID: 10176313
-
The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.JAMA. 2016 Aug 23-30;316(8):858-71. doi: 10.1001/jama.2016.11237. JAMA. 2016. PMID: 27552619 Review.
-
Determinants of Market Exclusivity for Prescription Drugs in the United States.JAMA Intern Med. 2017 Nov 1;177(11):1658-1664. doi: 10.1001/jamainternmed.2017.4329. JAMA Intern Med. 2017. PMID: 28892528 Review.
Cited by
-
Rebuttal: are drugs too expensive in Canada?Can Fam Physician. 2006 Jul;52(7):841-2, 843-5. Can Fam Physician. 2006. PMID: 16893142 Free PMC article. No abstract available.
-
Rare diseases, orphan drugs, and their regulation in Asia: Current status and future perspectives.Intractable Rare Dis Res. 2012 Feb;1(1):3-9. doi: 10.5582/irdr.2012.v1.1.3. Intractable Rare Dis Res. 2012. PMID: 25343064 Free PMC article. Review.
-
What is the value of 'me-too' drugs?Health Care Manag Sci. 2013 Dec;16(4):300-13. doi: 10.1007/s10729-013-9225-3. Epub 2013 Feb 26. Health Care Manag Sci. 2013. PMID: 23440390
-
Lessons for a national pharmaceuticals strategy in Canada from Australia and New Zealand.Can J Cardiol. 2007 Jul;23(9):711-8. doi: 10.1016/s0828-282x(07)70815-2. Can J Cardiol. 2007. PMID: 17622393 Free PMC article.
-
Competitive pricing within pharmaceutical classes: evidence on "follow-on" drugs in Germany 1993-2008.Eur J Health Econ. 2015 Jan;16(1):73-82. doi: 10.1007/s10198-013-0555-3. Epub 2013 Dec 27. Eur J Health Econ. 2015. PMID: 24370790
References
-
- A review of new drugs in 2004: floundering innovation and increased risk-taking. Prescrire Int 2005;14:68-73.
-
- Patented Medicine Prices Review Board (PMPRB). Annual report 2004. Ottawa: PMPRB; 2005.
-
- Lee TH. “Me-too” products — Friend or foe? [published erratum in N Engl J Med 2004;350(15):1586]. N Engl J Med 2004;350:211-2. - PubMed
-
- DiMasi JA. Price trends for prescription: pharmaceuticals: 1995–1999. Background report prepared for the US Department of Health and Human Services' Conference on Pharmaceutical Pricing Practices, Utilization and Costs; 2000 Aug 8–9; Washington, DC. Available: http://aspe.hhs.gov/health/reports/Drug-papers/dimassi/dimasi-final.htm (accessed 2006 Mar 6).
-
- Lu ZJ, Comanor WS. Strategic pricing of new pharmaceuticals. Rev Econ Stat 1998;80:108-18.
MeSH terms
LinkOut - more resources
Full Text Sources
